Compare Bristol-Myers Squibb Co (BMY) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs HubSpot Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while HubSpot Inc trades at $216.5 (market cap $10.73B). The key difference: Bristol-Myers Squibb Co is far larger — about 10.8× HubSpot Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| BMY | HUBS | |
|---|---|---|
Market Cap | $116.30B | $10.73B |
Sector | Health | Technology |
52-Week High | $62.37 | $560.90 |
52-Week Low | $42.60 | $170.39 |
Enterprise Value | $152.24B | $9.29B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HubSpot (HUBS) trades at $217.59, up 4.87% with a bullish technical signal. The stock shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53. Recent news highlights AI-driven expansion and customer growth, with the company hosting an Analyst Day in September 2026.
The outlook for HUBS is favorable due to robust fundamentals and AI integration, but risks include high valuation multiples and competitive pressures. Upside potential exists if earnings growth continues, though investors should monitor margin expansion and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
